ArticleNature communications2022
Collateral sensitivity to pleuromutilins in vancomycin-resistant Enterococcus faecium.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 39 citations in OpenAlex.
- CuBioactive materials · 2026Article
- Bacterial adaptation to essential oils and their main compounds in food systems: mechanisms related to antibacterial resistance.NPJ science of food · 2026Review
- Clade-specific evolution and genome plasticity underlying antimicrobial resistance in Enterococcus faecium.Archives of microbiology · 2026Review
- Comparative core-genome MLST of vancomycin-resistant Enterococcus faecium supports the utility of wastewater-based surveillance: a pilot study.BMC microbiology · 2026Article
- Ag-CuO Nanozymes Superior to Commercial Silver-Based Dressings: Synergistic Antibacterial Therapy via PTS-Mediated Starvation and Cuproptosis-Like Death.Research (Washington, D.C.) · 2026Article
- Repurposing antibacterial drugs identifies ridinilazole and CRS3123 as promising candidates against vancomycin-resistant enterococci.Scientific reports · 2025Article
- MDM2-P53-V-ATPases axis driven by dehydroevodiamine to fight intracellular bacterial infection.Communications biology · 2025Article
- Genomic surveillance of vancomycin-resistant Enterococcus faecium: a study on Resistome, Plasmidome, and mobilome profiling.Current genetics · 2025Article
- Review
- Cathelicidin AS-12W Derived from the Alligator sinensis and Its Antimicrobial Activity Against Drug-Resistant Gram-Negative Bacteria In Vitro and In Vivo.Probiotics and antimicrobial proteins · 2025Article
- Leveraging collateral sensitivity to counteract the evolution of bacteriophage resistance in bacteria.mLife · 2025Article
- Rational Design of Natural Xanthones Against Gram-negative Bacteria.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Deciphering vancomycin resistance inFrontiers in microbiology · 2025Article
- Tobramycin-resistant small colony variant mutant ofVirulence · 2024Article
- Persistence of Daptomycin-Resistant and Vancomycin-Resistant Enterococci in Hospitalized Patients with Underlying Malignancies: A 7-Year Follow-Up Study.Microorganisms · 2024Article
- Effects of dietary supplementation ofFrontiers in veterinary science · 2024Article
- Antibacterial activity and mechanism of Stevia extract against antibiotic-resistantFrontiers in microbiology · 2024Article
- Navigating collateral sensitivity: insights into the mechanisms and applications of antibiotic resistance trade-offs.Frontiers in microbiology · 2024Review
- Coumarin Glycosides Reverse Enterococci-Facilitated Enteric Infections.Research (Washington, D.C.) · 2024Article
- Collateral sensitivity profiling in drug-resistant Escherichia coli identifies natural products suppressing cephalosporin resistance.Nature communications · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 10 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The acquisition of resistance to one antibiotic sometimes leads to collateral sensitivity to a second antibiotic. Here, we show that vancomycin resistance in Enterococcus faecium is associated with a remarkable increase in susceptibility to pleuromutilin antibiotics (such as lefamulin), which target the bacterial ribosome. The trade-off between vancomycin and pleuromutilins is mediated by epistasis between the van gene cluster and msrC, encoding an ABC-F protein that protects bacterial ribosomes from antibiotic targeting. In mouse models of vancomycin-resistant E. faecium colonization and septicemia, pleuromutilin treatment reduces colonization and improves survival more effectively than standard therapy (linezolid). Our findings suggest that pleuromutilins may be useful for the treatment of vancomycin-resistant E. faecium infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.